Your session is about to expire
β Back to Search
iTEAR100 Therapy for Dry Eye Syndrome
Phase 4
Waitlist Available
Research Sponsored by Olympic Ophthalmics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Inclusion Criteria: Able to sign English language consent form and over age 18 and reside in the U.S.
-
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
Study Summary
A Usability Study of External Neuromodulation With iTEAR100 Generation 2. A study which evaluates user ability to train and access the iTEAR100 device in a telehealth environment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check βYesβ for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Usability
Secondary outcome measures
Adverse Events
Symptom Score
Symptom Scores
Trial Design
1Treatment groups
Experimental Treatment
Group I: iTEAR100 TherapyExperimental Treatment1 Intervention
Treatment Arm. Assessment of usability of generation 2 connected devices
Find a Location
Who is running the clinical trial?
Olympic Ophthalmics, Inc.Lead Sponsor
3 Previous Clinical Trials
265 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger